Influence of the <i>CYP3A5</i> and <i>MDR1</i> genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects

Abstract

This study shows that the CYP3A5*3 genetic polymorphisms may be associated with the individual difference in tacrolimus pharmacokinetics. An individualized dosage regimen design incorporating such genetic information would help increase clinical efficacy of the drug while reducing adverse drug reactions.